Rezera's ruvonoflast adds anti-inflammatory effect to semaglutide in Phase 2
Rezera says its drug ruvonoflast, taken alongside semaglutide, gave an extra anti-inflammatory benefit in the RESOLVE-2 trial.
Recap by typeshit. Full story at Dealroom.
Rezera says its drug ruvonoflast, taken alongside semaglutide, gave an extra anti-inflammatory benefit in the RESOLVE-2 trial.
Recap by typeshit. Full story at Dealroom.
In mice, GLP-1 receptor signaling mainly calmed inflammation while GLP-2 receptor signaling helped the intestine repair after T cell attack, researchers report.
Talker Research polled 2,000 Americans for aesthetics company Revance. Of 1,402 GLP-1 users, over 24% reported a new identity shift after starting the drugs.
Raw numbers pointed to higher AMD risk with GLP-1 drugs, but researchers say the pattern reversed once heart and metabolic factors were accounted for.
The Havre de Grace center opened a research building and will test whether the pairing cuts alcohol cravings. The study starts in early 2027, results about two years later.
He says he doesn't need to lose weight and started low doses for longevity, but wonders if it's too early to know benefits or long-term side effects.
Some women are crediting GLP-1 drugs with new chances at pregnancy. KATV cites a WHO figure that one in six people face infertility in their lifetime.
Loading…